Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2024.12.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Virginia Abello Polo und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical and Functional Unit for Leukemia Lymphoma Myeloma, GIGA Research Group, Cancer Treatment and Research Center Luis …. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Reddy's Laboratories, Takeda Pharmaceutical Company Limited, BeiGene Ltd.
Abstract (Originalsprache)
BACKGROUND: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. METHODS: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. RESULTS: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. CONCLUSIONS: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Clinical and Functional Unit for Leukemia Lymphoma Myeloma, GIGA Research Group, Cancer Treatment and Research Center Luis Carlos Sarmiento Angulo (CTIC), Bogotá, Colombia. Electronic address:…
- Department of Hematology, Fundación Oftalmológica de Santander Foscal and Fundación Fosunab, Universidad Autónoma de Bucaramanga (UNAB), Floridablanca, Colombia.
- HEMORIO, University Federal Rio de Janeiro, Rio de Janeiro, Brazil.
- Hematology Department, HematoOncólogos Asociados, Bogotá, Colombia.
- Hematology Department, IDC Hemato Oncólogos, Cali, Colombia.
- Hematology Department, Hospital de San José, Bogotá, Colombia.
Förderung
- Dr. Reddy's Laboratories
- Takeda Pharmaceutical Company Limited
- BeiGene Ltd
- F Hoffmann-La Roche Ltd
- Janssen Pharmaceuticals Inc
- Amgen Inc
- Novartis Pharmaceuticals Corporation
- AbbVie Inc
Zitieren
APA
Abello Polo, V., Sossa, C., Boquimpani, C., Salazar, L. A., Munevar, I., Gómez, R., Cuervo, D. M., Varón Jaimes, C., Reyes, J., Idrobo, H., Omaña, P., Daza, J., Pedraza Morales, J. E., Agudelo López, C., Quintero-Vega, G. E., Correa Correa, M., Herrera, J. M., Mantilla, W. A., Serrano, J. C., …, & Lobatón Ramírez, J. F. (2025). Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.12.015
Vancouver
Abello Polo V, Sossa C, Boquimpani C, Salazar LA, Munevar I, Gómez R, et al. Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.12.015
BibTeX
@article{AbelloPolo2025,
author = {Abello Polo, Virginia and Sossa, Claudia and Boquimpani, Carla and Salazar, Luis Antonio and Munevar, Isabel and Gómez, Rigoberto and Cuervo, Diana Marcela and Varón Jaimes, Carlos and Reyes, Jheremy and Idrobo, Henry and Omaña, Paola and Daza, Jorge and Pedraza Morales, Julian Eduardo and Agudelo López, Claudia and Quintero-Vega, Guillermo E and Correa Correa, Mario and Herrera, Juan Manuel and Mantilla, William Armando and Serrano, Juan Carlos and Rosales, Carmen and Gálvez Cárdenas, Kenny Mauricio and Bermúdez, Carlos and Saavedra Ramírez, Domingo and Alzate, Mauricio and Lobatón Ramírez, José Fernando},
title = {Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2024.12.015}
}
EUVIMED